|
|||||
|
|
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
|
| Authors: | Coates Laura C Mease Philip Kronbergs Andris Helt Cameron Sandoval David Park So Young Combe Bernard Nash Peter Deodhar Atul |
| Institution: | 1.Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK ;2.Swedish Medical Center/Providence St, Joseph Health and University of Washington, Seattle, WA, USA ;3.Eli Lilly and Company, Indianapolis, IN, USA ;4.University of Montpellier, Montpellier, France ;5.Department of Medicine, University of Queensland, Queensland, Brisbane, Australia ;6.Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, Portland, OR, 97239, USA ; |
| Abstract: | Clinical Rheumatology - To evaluate the three-year efficacy and safety of ixekizumab with and without concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) use in... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |